nach oben

European Journal of Pediatrics

Erschienen in:

20.07.2017 | Review

Biologics in juvenile idiopathic arthritis: a narrative review

verfasst von: Federica Vanoni, Francesca Minoia, Clara Malattia

Erschienen in: European Journal of Pediatrics | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

In the past years, pediatric rheumatology has seen a revolution in the treatments for rheumatic diseases, particularly juvenile idiopathic arthritis. Even if nonsteroidal anti-inflammatory drugs (NSAID), intra-articular corticosteroids (IAC) injections, and methotrexate remain the mainstay of the treatment for JIA patients, in aggressive disease, these treatments may be not sufficient to reach disease remission and to prevent long-term disability. Comprehension of immunological mechanisms involved in the pathogenesis of the diseases allowed to conceive new drugs targeting specific steps of the immune response. Several cytokines, like TNF alpha and IL-1, represent a very interesting target for biologic therapies. Due to the efficacy of these therapies, nowadays, “disease remission” in pediatric rheumatology is more and more frequent, especially in juvenile idiopathic arthritis patients, and the long-term outcomes have been significantly improved. Crucial to these advancements have been multicenter controlled clinical trials and long-term safety monitoring.

Conclusions: Research in pediatric rheumatology has resulted in dramatic advances in diseases management. Biologic treatments have improved physical and functional outcomes and quality of life of patients with rheumatic disease.

What is Known:

• NSAID, intra-articular injection of corticoids, and methotrexate are the mainstay in treatment of JIA.

• In aggressive JIA, these treatments may be not sufficient to reach disease remission and to prevent long term disability.

What is New:

• In recent years, management of JIA has significantly improved with the development of biologic therapies that allowed children with arthritis to reach a normal growth and to achieve a good long-term functional outcome.

Aksentijevich I, Masters SL, Ferguson PJ et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360:2426–2437CrossRefPubMedPubMedCentral

Alexeeva EI, Valieva SI, Bzarova TM et al (2011) Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 30(9):1163–1172CrossRefPubMed

Atzeni F, Talotta R, Salaffi F et al (2013) Immunogenicity and autoimunity during anti TNF therapy. Autoimmun Rev 12:703CrossRefPubMed

Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD (2012) Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64(4):1263–1271CrossRefPubMedPubMedCentral

Beukelman T, Xie F, Chen L et al (2012) Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64(8):2773–2780CrossRefPubMedPubMedCentral

Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F (2001) Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 17:23–27CrossRef

Brunner H, Ruperto N, Tzaribachev N et al (2014) A148: a multi-center, double-blind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results. Arthritis Rheum 66:S191–S192CrossRef

Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-Pérez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, Gámir ML, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F, Paediatric Rheumatology International Trials Organisation PRINTO; Pediatric Rheumatology Collaborative Study Group (PRCSG) (2015) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74(6):1110–1117CrossRefPubMed

Carrasco R, Smith JA, Lovell D (2004) Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs 6:137–146CrossRefPubMed

10.

De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2385–2395CrossRefPubMed

11.

De Benedetti F, Martini A (1998) Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 25:203–207PubMed

12.

De Benedetti F, Ravelli A, Martini A (1997) Cytokines in juvenile rheumatoid arthritis. Curr Opin Rheumatol 9:428–433CrossRefPubMed

13.

Diak P, Siegel J, La Grenade L et al (2010) Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 62(8):2517–2524CrossRefPubMed

14.

Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, Delfino L, Ferlito F, Pelagatti MA, Caroli F, Buoncompagni A, Viola S, Loy A, Sironi M, Vecchi A, Ravelli A, Martini A, Rubartelli A (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58:1505–1515CrossRefPubMed

15.

Halbig M, Horneff G (2009) Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int 30(2):229–238CrossRefPubMed

16.

Horneff G, Becker I, On behalf of German and Austrian Collaborative BIKER study group (2014) Serious infections in juvenile idiopathic arthritis patients upon TNF inhibitors depend on disease activity. Arthritis Rheum 73(suppl 2):114–115

17.

Hoxha A, Calligaro A, Tonello M, Ramonda R, Carletto A, Paolazzi G, Bortolotti R, Del Ross T, Grava C, Boaretto M, Favaro M, Teghil V, Ruffatti A, Punzi L (2016) The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a prospective multicentre study. Joint Bone Spine 3(2):167–171CrossRef

18.

Kelly A, Ramanan AV (2008) A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 4:615–620CrossRefPubMed

19.

Kietz DA, Pepmueller PH, Moore TL (2002) Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum 61(2):171–173CrossRef

20.

Kobayashi M, Takahashi Y, Yamashita H et al (2011) Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome. Mod Rheumatol 21(1):92–96CrossRefPubMed

21.

Kuek A, Hazleman BL, Gaston JH et al (2006) Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology (Oxford) 45(11):1448–1449CrossRef

22.

Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner J et al (2009) Efficacy and safety of canakinumab (ACZ885), a fully human anti-interleukin-1beta antibody, in cryopyrinassociated periodic fever syndrome: results of a multicenter, randomized, double-blind, phase III study. Rheumatology 48:i34–i35

23.

Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group. N Engl J Med 342:763–769CrossRefPubMed

24.

Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ (2013) Long-term safety and efficacy of rilonacept in patient with systemic juvenile arthritis. Arthritis Rheum 65:2486–2496CrossRefPubMed

25.

Lovell DJ, Reiff A, Ilowite NT et al (2008) Pediatric rheumatology collaborative study group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58:1496–1504CrossRefPubMed

26.

Lovell DJ, Ruperto N, Goodman S et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810–820CrossRefPubMed

27.

Lurati A, Teruzzi B, Salmaso A et al (2005) Macrophage activation syndrome (MAS) during anti-IL1 therapy (anakinra) in a patient affected by systemic juvenile arthritis (soJIA): a report and review of the literature. Pediatr Rheumatol 3:79–85

28.

Maini SR (2004) Infliximab treatment of rheumatoid arthritis. Rheum Dis Clin N Am 30(2):329–347CrossRef

29.

Nigrovic PA, Mannion M, Prince FH et al (2011) Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63(2):545–555CrossRefPubMed

30.

Pascual V, Allantaz F, Arce E et al (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201(9):1479–1486CrossRefPubMedPubMedCentral

31.

Peres-Alvarez R, Pérez-de-Lis M, Ramos-Casals M, BIOGEAS study group (2013) Biologic induced autoimmune diseases. Curr Opin Rheumatol 25:56CrossRef

32.

Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392PubMed

33.

Prahalad S, Bove KE, Dickens D et al (2001) Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 28(9):2120–2124PubMed

34.

Quartier P, Taupin P, Bourdeaut F et al (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48(4):1093–1101CrossRefPubMed

35.

Ramanan AV, Schneider R (2003) Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 30(2):401–403PubMed

36.

Ringold S et al (2014) Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res 66(7):1063–1072CrossRef

37.

Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovel DJ, Nigrovic PA, Robinson AB, Vehe RK (2013) Recommendations for the treatment of juvenile idiopathic arthritis. Arthritis & Rheum 65(10):2499–2512CrossRef

38.

Robinson RF, Nahata MC, Hayes JR et al (2003) Quality-of-life measurements in juvenile rheumatoid arthritis patients. Clin Drug Investig 23(8):511–518CrossRefPubMed

39.

Ruperto N, Brunner HI, Quartier P et al (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367(25):2396–2406CrossRefPubMed

40.

Ruperto N, Lovell DJ, Cuttica R et al (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56:3096–3106CrossRefPubMed

41.

Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pèrez N, Silva CA et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled withdrawal trial. Lancet 372:383–391CrossRefPubMed

42.

Ruperto N, Quartier P, Wulffraat N et al (2012) A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 64(2):557–567CrossRefPubMed

43.

Schmeling H, Horneff G (2005) Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 44:1008–1011CrossRef

44.

Simard JF, Neovius M, Hagelberg S, Askling J (2010) Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 62(12):3776–3782CrossRefPubMed

45.

Tappeiner C, Mesquida M, Adán A, Anton J, Ramanan AV, Carreno E, Mackensen F, Kotaniemi K, de Boer JH, Bou R, de Vicuña CG, Heiligenhaus A Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016.

46.

Tynjala P, Lindahl P, Honkanen V et al (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66(4):548–550CrossRefPubMed

47.

Tynjala P, Vahasalo P, Tarkiainen M et al (2001) Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTEJIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis 70(9):1605–1612CrossRef

48.

van Oosten BW, Barkhof F, Truyen L et al (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531CrossRefPubMed

49.

Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, Wulffraat NM (2014) Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 66(4):1034–1043CrossRefPubMed

50.

Verbsky JW, White AJ (2004) Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 31(10):2071–2075PubMed

51.

Vojvodich PF, Hansen JB, Andersson U et al (2007) Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. J Rheumatol 34(12):2481–2485PubMed

52.

Yokota S, Imagawa T, Mori M, Miyamae T, Amhara Y, Takei S et al (2008) Efficacy and safety of tocilizumab in patients with systemic onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371:998–1006CrossRefPubMed

53.

Zannin ME, Birolo C, Gerloni VM et al (2013) Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow-up data from the italian registry. J Rheumatol 40(1):74–79CrossRefPubMed

54.

Zeft A, Hollister R, LaFleur B et al (2009) Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 15(4):161–164CrossRefPubMed

Titel: Biologics in juvenile idiopathic arthritis: a narrative review
verfasst von: Federica Vanoni
Francesca Minoia
Clara Malattia
Publikationsdatum: 20.07.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Pediatrics / Ausgabe 9/2017
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-017-2960-6

Neu im Fachgebiet Pädiatrie

23.04.2024 | Typ-1-Diabetes | Nachrichten

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Biologics in juvenile idiopathic arthritis: a narrative review

Abstract

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2017

Patient experience in the pediatric emergency department: do parents and children feel the same?

The effect of early feeding practices on growth indices and obesity at preschool children from four European countries and UK schoolchildren and adolescents

Imaging in children with unilateral ureteropelvic junction obstruction: time to reduce investigations?

Clinical characteristics and prognosis of pediatric cryptococcosis in Beijing Children’s Hospital, 2002–2014

Early hypovolemic shock and abdominal distention due to neonatal splenic rupture: urgency of diagnosis and management

Renal function in neonates with twin-twin transfusion syndrome treated with or without fetoscopic laser surgery

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie